This Article Full Text Full Text (PDF) All Versions of this Article: 118/14/1450    most recent CIRCULATIONAHA.108.782300v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morales, J. R. Articles by Moro, M. A. Search for Related Content PubMed PubMed Citation Articles by Morales, J. R. Articles by Moro, M. A. Related Collections Genetically altered mice Neuroprotectors Other Stroke Treatment - Medical Lipid and lipoprotein metabolism Related Article

(Circulation. 2008;118:1450-1459.)
© 2008 American Heart Association, Inc.

Stroke

Activation of Liver X Receptors Promotes Neuroprotection and Reduces Brain Inflammation in Experimental Stroke

Jesús R. Morales, BPharm; Iván Ballesteros, BSc; José Manuel Deniz, BSc; Olivia Hurtado, PhD; José Vivancos, MD, PhD; Florentino Nombela, MD; Ignacio Lizasoain, MD, PhD; Antonio Castrillo, PhD; María A. Moro, PhD

From the Department of Pharmacology, School of Medicine, Universidad Complutense de Madrid, Madrid (J.R.M., I.B., O.H., I.L., M.A.M.); School of Medicine, Universidad de Las Palmas, Las Palmas de Gran Canaria (J.M.D., A.C.); and Hospital Universitario La Princesa, Madrid (J.V., F.N.), Spain.

Correspondence to María A. Moro, Department of Pharmacology, School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain. E-mail neurona{at}med.ucm.es

Received June 8, 2007; accepted July 29, 2008.

Background— The liver X receptors (LXRs) belong to the nuclear receptor superfamily and act as transcriptional regulators of cholesterol metabolism in several tissues. Recent work also has identified LXRs as potent antiinflammatory molecules in macrophages and other immune cells. Combined changes in lipid and inflammatory profiles are likely mediating the protective role of LXRs in models of chronic injury like atherosclerosis. These beneficial actions, however, have not been illustrated in other models of acute injury such as stroke in which inflammation is an important pathophysiological feature.

Methods and Results— We have studied LXR expression and function in the course of experimental stroke caused by permanent middle cerebral artery occlusion in rats and mice. Here, we show that administration of the synthetic LXR agonists GW3965 or TO901317 after the ischemic occlusion improves stroke outcome as shown by decreased infarct volume area and better neurological scores in rats. Neuroprotection observed with LXR agonists correlated with decreased expression of proinflammatory genes in the brain and with reduced nuclear factor-B transcriptional activity. Loss of function studies using LXR,β^–/– mice demonstrated that the effect of LXR agonists is receptor specific. Interestingly, infarcted brain area and inflammatory signaling were significantly extended in LXR,β^–/– mice compared with control animals, indicating that endogenous LXR signaling mediates neuroprotection in this setting.

Conclusion— This work highlights the transcriptional action of LXR as a protective pathway in brain injury and the potential use of LXR agonists as therapeutic agents in stroke.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 118: 1403-1404. [Extract] [Full Text]

This article has been cited by other articles:

				J. Chen, X. Cui, A. Zacharek, C. Roberts, and M. Chopp eNOS Mediates TO90317 Treatment-Induced Angiogenesis and Functional Outcome After Stroke in Mice Stroke, July 1, 2009; 40(7): 2532 - 2538. [Abstract] [Full Text] [PDF]

				C. J. Nelson, J. P. Otis, and H. V. Carey A role for nuclear receptors in mammalian hibernation J. Physiol., May 1, 2009; 587(9): 1863 - 1870. [Abstract] [Full Text] [PDF]

				C. Gabbi, M. Warner, and J.-A. Gustafsson Minireview: Liver X Receptor {beta}: Emerging Roles in Physiology and Diseases Mol. Endocrinol., February 1, 2009; 23(2): 129 - 136. [Abstract] [Full Text] [PDF]